tiprankstipranks
LadRx Strategic Shifts in Licensing and Royalty Agreements
Company Announcements

LadRx Strategic Shifts in Licensing and Royalty Agreements

Don't Miss our Black Friday Offers:

The latest update is out from LadRx (LADX).

On June 3, 2024, LadRx Corporation ended its exclusive worldwide license agreement for aldoxorubicin with NantCell, clearing all obligations except potential negotiations for LadRx to buy remaining aldoxorubicin inventory. Concurrently, LadRx amended its royalty agreement with XOMA, outlining new royalty payments if LadRx commercializes aldoxorubicin itself or licenses it to a third party. These strategic moves could reshape LadRx’s future revenue streams and impact investor outlook on the company’s market position.

Learn more about LADX stock on TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App